Weight Loss

Tirzepatide

Dual GIP + GLP-1 agonist. SURMOUNT-1 trial: 22.5% average body weight loss at 72 weeks. Over half of max-dose patients lost 20%+.

Ongoing, escalating
2.5mg → 15mg/week
First effects: Weeks 1-4
SubQ weekly

Interactive Timeline

Appetite
Weight Loss
Energy/Joints
Side Effects
Blood Sugar
Weeks 1-4
Weeks 5-8
Weeks 9-16
Weeks 17-24
Month 6-12
Month 12+

Tap dots for details. Scroll horizontally to see full timeline.

Weeks 1-4

Toleration Phase

  • 2.5mg starting dose
  • 2-4 lbs initial loss
  • GI side effects peak here

By week 3 I had lost 8 lbs. Wasn't even trying to diet.

Weeks 5-8

Food Chatter Stops

  • 5mg dose
  • 3-5% body weight loss
  • Appetite fundamentally changed

Something clicked. Food chatter just... stopped.

Weeks 9-16

Fastest Loss Rate

  • 7.5-10mg dose
  • Peak weekly loss rate
  • Joint pain improving

Week 12 down 23 lbs. My knees don't hurt anymore.

Weeks 17-24

Approaching Target

  • 10-15mg dose
  • ~15% body weight loss
  • Better tolerated than semaglutide

Faster, stronger, less nausea than Ozempic.

Month 6-12+

Clinical Results

  • 22.5% average at 72 weeks
  • Over half lost 20%+
  • Bariatric-level results

Results that used to require bariatric surgery.

Dosing Protocol

2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg progressive escalation

All timelines reflect community-reported observations. Not medical advice. Individual results vary. Consult a qualified healthcare provider before starting any peptide protocol.

DYK Peptides

Community-reported peptide data